Use of sulfanegen and its analogs for prevention and treatment for neurodegenerative disorders
A 3-mercaptopyruvate prodrug, sulfanegen, that reduces neuroinflammation and oxidative stress for therapeutic use in neurodegenerative diseases.
Technology No. 2020-331
1
2
3
IP Status: Issued US Patent; Issued Patent No.11,925,623
In vitro neuroprotection studies and in vivo studies with biochemical and T-maze cognitive assessment tests have been conducted for sulfanegen. The researchers are currently evaluating the brain tissues of these mice for detailed mechanistic understanding of sulfanegen's neuroprotective action.
Applications
- Alzheimer’s Disease
- Parkinson's Disease
- Huntington's Disease
- Cognitive Impairment
- Non-Alcoholic Fatty Liver Disease/Non-alcoholic steatohepatitis (NAFLD/NASH)
- Tylenol (acetaminophen) toxicity
Technology Overview
Sulfanegen is a prodrug of 3-mercaptopyruvic acid. Sulfanegen was studied for potential therapeutic benefit in Alzheimer's mouse models. In mice, sulfanegen at both doses 50 and 100 mg/kg showed a marked improvement in Alzheimer’s pathology and cognitive behavior pattern as determined by the T-maze spontaneous alternation.
Phase of Development
TRL: 3-4In vitro neuroprotection studies and in vivo studies with biochemical and T-maze cognitive assessment tests have been conducted for sulfanegen. The researchers are currently evaluating the brain tissues of these mice for detailed mechanistic understanding of sulfanegen's neuroprotective action.
Desired Partnerships
This technology is now available for:- License
- Sponsored research
- Co-development
Please contact our office to share your business’ needs and learn more.
Researchers
- Robert Vince Professor and Director, Center for Drug Design
- Swati Sudhakar More Associate Professor, Center for Drug Design
-
swap_vertical_circlelibrary_booksReferences (5)
- More SS, Beach JM, McClelland C, Mokhtarzadeh A, Vince R. (2019), In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease
- Patterson SE, Moeller B, Nagasawa HT, Vince R, Crankshaw DL, Briggs J, Stutelberg MW, Vinnakota CV, Logue BA (2011), Development of sulfanegen for mass cyanide casualties.
- Patterson SE, Monteil AR, Cohen JF, Crankshaw DL, Vince R, Nagasawa HT (2013), Cyanide antidotes for mass casualties: water-soluble salts of the dithiane (sulfanegen) from 3- mercaptopyruvate for intramuscular administration
- Rao SP, Xie W, Kwon YIC, Juckel N, Xie J, Dronamraju VR, Vince R, Lee MK, More SS (2022), Sulfanegen stimulates 3-mercaptopyruvate sulfurtransferase activity and ameliorates Alzheimer's disease pathology and oxidative stress in vivo
- Swetha Pavani Rao, Wei Xie, Ye In Christopher Kwon, Nicholas Juckel, Jiashu Xie, Venkateshwara Rao Dronamraju, Robert Vince, Michael K. Lee, Swati S. More , Sulfanegen stimulates 3-mercaptopyruvate sulfurtransferase activity and ameliorates Alzheimer's disease pathology and oxidative stress in vivo, Redox Biology
-
swap_vertical_circlecloud_downloadSupporting documents (1)Product brochureUse of sulfanegen and its analogs for prevention and treatment for neurodegenerative disorders.pdf